Ovagen
A short synthetic Khavinson-class peptide bioregulator variously positioned for ovarian/reproductive and hepatic tissue support through epigenetic gene-expression modulation.
Ovagen is a short synthetic peptide developed by Vladimir Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology, part of the Khavinson organ-specific bioregulator family. Sources disagree on its target and structure: it is described both as an ovarian/reproductive bioregulator (tetrapeptide Lys-Glu-Asp-Gly, KEDG) and as a liver/GI-targeted bioregulator (tripeptide Glu-Asp-Leu). Its proposed mechanism is the standard Khavinson model of passive cell entry, nuclear import, and sequence-selective chromatin modulation of tissue-specific gene programs. Evidence is preclinical and Khavinson-group-derived, with no FDA/EMA approval and no indexed human clinical trials specific to Ovagen.
Class
Synthetic short-chain Khavinson peptide bioregulator (tri- or tetrapeptide)
Routes
oral, sublingual, subcutaneous
Category
Longevity & Bioregulators
Researched benefits
What it's studied for
Ovarian and reproductive tissue support (claimed)
Positioned as the female-reproductive counterpart to Testagen, Ovagen is claimed to support follicular reserve markers, granulosa cell function, and steroidogenic programs in aging ovarian tissue. Evidence is limited to Russian in vitro follicle-culture work and small uncontrolled observational series in perimenopausal women.
Hepatic function and regeneration (claimed)
Several sources place Ovagen as a liver/GI-targeted bioregulator proposed to modulate hepatocyte gene expression, support liver cell regeneration, normalize enzyme function, and aid hepatic protein synthesis. Preclinical rodent liver-injury models are cited but not independently replicated.
Anti-apoptotic / cytoprotective activity
In vitro Russian work reports preserved cell viability under stress and reduced apoptosis markers (e.g., in cultured granulosa cells), consistent with the general Khavinson bioregulator claim of promoting tissue-specific survival transcription programs.
Longevity and anti-aging framing
As an organ-specific Khavinson bioregulator, Ovagen is used within longevity rotation protocols aimed at restoring tissue-specific physiological parameters in aging, based on class-level rather than compound-specific evidence.
Mechanism
How it works
Ovagen is proposed to work through the standard Khavinson short-peptide bioregulator model: as a small, sufficiently polar peptide it passively crosses cell membranes, enters the nucleus, and binds DNA regulatory sequences in a sequence-selective manner to activate tissue-specific gene-expression programs. Tritiated-peptide biodistribution work from the Khavinson group describes uptake across multiple tissues including ovary, liver, kidney, and brain.
The sources disagree on which tissue Ovagen targets and on its structure. Some describe it as an ovarian bioregulator with the tetrapeptide sequence Lys-Glu-Asp-Gly (KEDG), proposed to reach granulosa and theca cell nuclei and preferentially upregulate follicular-survival, steroidogenic, and anti-apoptotic programs. Others place it as a liver/GI-targeted bioregulator with the tripeptide sequence Glu-Asp-Leu, proposed to modulate hepatocyte gene expression involved in protein synthesis and liver regeneration.
No GPCR, nuclear receptor, or defined enzyme target has been identified for Ovagen; it does not bind estrogen, progesterone, FSH, LH, or GnRH receptors. The absence of a defined molecular target is characteristic of the Khavinson bioregulator class, and the tissue-specific targeting claim rests on extrapolation from the broader bioregulator framework rather than modern structural biology, transcriptomic, or pharmacokinetic validation.
A conservative alternative interpretation treats Ovagen as an amino-acid source delivering lysine, glutamate, aspartate, and glycine (or glutamine) in a rapidly hydrolyzed short-peptide form, in which any observed effects could reflect substrate delivery for protein synthesis, glycine-mediated antioxidant (glutathione) support, or non-specific nutritional support under oxidative stress rather than sequence-specific chromatin modulation.
Dosing protocols
Dosing & administration
Dosing reflects protocols reported in research and community literature for educational purposes. It is not medical advice or a recommendation. Most peptides here are not approved for human use.
Reconstitution
For synthetic lyophilized KEDG peptide from research suppliers: warm the vial to room temperature, flick to dislodge the lyophilisate, clean the stopper, and add 2 mL bacteriostatic water to a 5 mg vial for a 2.5 mg/mL concentration (inject slowly down the glass, dissolve 5-10 min). At 2.5 mg/mL: 2 mg = 0.8 mL (80 units on a U100 syringe), 2.5 mg = 1.0 mL, 5 mg = 2.0 mL. Store at 2-8 C (do not freeze); ~28-30 day stability; discard if cloudy.
Beginner
- Dose
- 1 capsule (20 mg nominal)
- Frequency
- Once daily
- Timing
- Sublingual or oral on an empty stomach, 30-45 min before breakfast
- Duration
- 10 consecutive days, then 60-day washout
- Route
- Oral / sublingual
Use a product with third-party HPLC and a certificate of analysis. Keep a baseline cycle/symptom diary and endocrine labs (FSH, estradiol, AMH, TSH). Continue existing reproductive care; do not stop HRT, contraception, or fertility treatment to test Ovagen.
Intermediate
- Dose
- 20 mg oral daily OR 2-5 mg SC daily
- Frequency
- Once daily
- Timing
- Empty stomach (oral); no specific menstrual-cycle phase timing
- Duration
- 10 consecutive days per cycle, cycled roughly twice yearly
- Route
- Oral / sublingual or subcutaneous
For experienced bioregulator users. Often rotated with Epitalon, Pinealon, and Thymogen. Continue evidence-graded reproductive care; treat the bioregulator as an experimental layer. Annual reproductive endocrine panel recommended.
Advanced
- Dose
- 20 mg oral/sublingual daily OR up to 5 mg SC daily
- Frequency
- Once daily
- Timing
- Within a structured annual Khavinson rotation
- Duration
- 10-day pulses (e.g., Month 1 and Month 10 Ovagen) separated by 2-3 month washouts, alternating with Epitalon and Pinealon
- Route
- Oral / sublingual or subcutaneous
For experienced users with a stable reproductive-hormone baseline, layered on an evidence-graded base (hormone therapy if indicated, myo-inositol, vitamin D, omega-3, CoQ10). Requires reproductive endocrinologist coordination. Do not run during active IVF or fertility treatment without explicit approval.
- A 20 mg oral capsule contains an undisclosed actual KEDG content (historically estimated at 2-4 mg, the balance being excipients).
- Do not exceed 20 mg oral or 5 mg SC per day, and do not run continuous cycles — the safety of continuous exposure is unstudied.
- No dose-ranging trial establishes 20 mg as optimal; dosing follows Khavinson convention rather than modern pharmacology.
- Avoid during pregnancy, breastfeeding, and active conception attempts. Avoid in eGFR <30 or decompensated hepatic disease; no formal dose adjustment exists for renal/hepatic impairment.
- Intravaginal or topical use is not a Khavinson convention and has no published protocol or sterility guidance — not advised.
- Set realistic expectations: a 10-day bioregulator cycle will not regrow oocytes, reverse established menopause, or restore fertility, and reported subjective effects are typically mild.
Evidence
Research & clinical studies (1)
Peptides and ageing
Khavinson review describing isolation and characterization of tissue-derived regulatory peptides including Ovagen, documenting tissue-trophic effects and its role within the broader Khavinson geroprotective peptide system for organ-targeted longevity support.
PMID 12374906Combinations
Stacking & blends
Khavinson Reproductive Rotation
Longevity-oriented tissue-specific bioregulator cycling
Ovagen is rotated in 10-day pulses with pineal bioregulators (Epitalon for telomerase/circadian support, Pinealon for HPG-axis support) across the year, separated by washouts, as an experimental add-on to evidence-graded care.
Couples Reproductive Pairing
Male and female reproductive-tissue support
Ovagen (positioned as female-reproductive) is paired with Testagen (male-reproductive counterpart) within the Khavinson framework, run as separate cycles for each partner.
Reproductive Peptide Adjuncts
Reproductive-axis exploratory support
Listed as compatible interactions; both Kisspeptin-10 and Gonadorelin act on characterized reproductive-axis targets and are noted as compatible with Ovagen in interaction data, though no formal combination studies exist.
Safety
Side effects & considerations
Commonly reported effects
Contraindications & cautions
- Pregnancy
- Breastfeeding
- Active conception attempts (pending safety data)
- Pediatric and adolescent use
- Hormone-sensitive cancer (breast, endometrial, ovarian, cervical)
- Unexplained abnormal uterine bleeding
- Active pelvic mass or gynecological pathology under investigation
- Known hypersensitivity to Ovagen or any Khavinson bioregulator
- Severe liver disease or decompensated hepatic disease
- Severe renal impairment (eGFR <30)
Short-term safety signals from Russian literature are mild, but long-term pharmacovigilance is absent and no Western-standard trials exist. Given the reproductive/hormonal framing, theoretical concerns about hormone-sensitive tumor risk and endometrial effects apply. Active IVF/fertility treatment, recent pelvic surgery, VTE/thrombophilia history, and hormone-sensitive benign conditions warrant supervised use only. Use only third-party HPLC-verified product with gynecological or medical oversight.
FAQ
Ovagen — common questions
Is Ovagen for the liver or the ovaries?
Sources disagree. Despite the name suggesting an ovarian target, some published Khavinson literature and vendor descriptions place Ovagen as a liver/GI-targeted bioregulator (tripeptide Glu-Asp-Leu), while others describe it as an ovarian/female-reproductive bioregulator (tetrapeptide Lys-Glu-Asp-Gly). Naming in the Khavinson cluster sometimes reflects historical research designations rather than transparent organ targeting.
What does Ovagen do?
It is proposed to act on target tissue through epigenetic gene-expression (chromatin) modulation, with preclinical research focused on tissue-specific survival, steroidogenic, or hepatocyte-function markers. Human Phase 2/3 efficacy has not been established at Western clinical standards.
Does Ovagen actually help with perimenopause or fertility?
The evidence is thin. Russian uncontrolled observational series report subjective symptom improvement and modest biomarker changes, but there are no placebo-controlled RCTs and no fertility outcome data (pregnancy or live-birth rates). It is best regarded as a speculative adjunct, not a substitute for evidence-graded hormone therapy or reproductive medicine.
What is the typical Ovagen dose?
Khavinson convention is a 20 mg oral/sublingual capsule once daily for 10 consecutive days with 60-90 day washouts, or 2-5 mg subcutaneously daily for 10 days for synthetic peptide. A 20 mg capsule contains an undisclosed actual peptide content (historically ~2-4 mg). No dose-ranging trial establishes 20 mg as optimal.
Is Ovagen safe?
Short-term safety signals are mild (occasional nausea, headache, transient cycle variation, rare rash, injection-site reactions), but long-term safety in humans is uncharacterized. Absolute contraindications include pregnancy, breastfeeding, active conception attempts, hormone-sensitive cancer, and unexplained uterine bleeding.
Is Ovagen legal and FDA-approved?
Ovagen is not approved by the FDA, EMA, or any major Western regulator, and no active approval pathway exists as of 2026. It is generally legal to purchase as a research chemical for laboratory use but is not approved for human consumption in Western markets.
How can I verify an Ovagen vendor?
Require an independent third-party HPLC certificate of analysis from a lab the vendor does not own or pay, ideally with mass spectrometry identity confirmation of the sequence and endotoxin testing. Independent purity testing is the standard quality signal.
